Orynotides are engineered analogs of theta-defensins, macrocyclic peptide molecules that occur naturally in some species of primates, but not humans. Exploiting the properties of these nonhuman primate molecules, Oryn is employing a novel retro-evolutionary approach to drug discovery for research and development of new therapeutics for several clinical indications.
Oryn’s lead Orynotide therapeutic candidate ORTD-1 induced long-lasting disease remission in preclinical models of rheumatoid arthritis. ORTD-1 has the potential to arrest disease in RA patients, providing major enhancement in quality of life without risks associated with immunosuppressive drugs currently in use, including many carrying black box warnings. A Phase 1a clinical trial of ORTD-1 demonstrated safety in healthy volunteers, and a Phase 1b trial in patients with stable rheumatoid arthritis was recently launched.
The therapeutic mechanism of ORTD-1 is predicted to be efficacious against lung inflammation that occurs in SARS-CoV-2 infection (COVID-19). In late 2020, the FDA authorized a Phase 1b/2 clinical trial of safety and efficacy of intravenous ORTD-1 in COVID-19 pneumonia which was recently launched.